New Dual Antimicrobial Effective for Nosocomial Pneumonia New Dual Antimicrobial Effective for Nosocomial Pneumonia

The combined antibacterial ceftolozane-tazobactam, sold as Zerbaxa by Merck, is a safe and effective option for nosocomial pneumonia, according to results of the noninferiority trial that led to approval of the drug for this indication in the U.S. in June.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news